Literature DB >> 11557745

Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation.

C A Carnes1, M K Chung, T Nakayama, H Nakayama, R S Baliga, S Piao, A Kanderian, S Pavia, R L Hamlin, P M McCarthy, J A Bauer, D R Van Wagoner.   

Abstract

Atrial fibrillation (AF), the most common chronic arrhythmia, increases the risk of stroke and is an independent predictor of mortality. Available pharmacological treatments have limited efficacy. Once initiated, AF tends to self-perpetuate, owing in part to electrophysiological remodeling in the atria; however, the fundamental mechanisms underlying this process are still unclear. We have recently demonstrated that chronic human AF is associated with increased atrial oxidative stress and peroxynitrite formation; we have now tested the hypothesis that these events participate in both pacing-induced atrial electrophysiological remodeling and in the occurrence of AF following cardiac surgery. In chronically instrumented dogs, we found that rapid (400 min(-1)) atrial pacing was associated with attenuation of the atrial effective refractory period (ERP). Treatment with ascorbate, an antioxidant and peroxynitrite decomposition catalyst, did not directly modify the ERP, but attenuated the pacing-induced atrial ERP shortening following 24 to 48 hours of pacing. Biochemical studies revealed that pacing was associated with decreased tissue ascorbate levels and increased protein nitration (a biomarker of peroxynitrite formation). Oral ascorbate supplementation attenuated both of these changes. To evaluate the clinical significance of these observations, supplemental ascorbate was given to 43 patients before, and for 5 days following, cardiac bypass graft surgery. Patients receiving ascorbate had a 16.3% incidence of postoperative AF, compared with 34.9% in control subjects. In combination, these studies suggest that oxidative stress underlies early atrial electrophysiological remodeling and offer novel insight into the etiology and potential treatment of an enigmatic and difficult to control arrhythmia. The full text of this article is available at http://www.circresaha.org.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11557745     DOI: 10.1161/hh1801.097644

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  144 in total

Review 1.  Diet and risk of atrial fibrillation – epidemiologic and clinical evidence –.

Authors:  Noelle N Gronroos; Alvaro Alonso
Journal:  Circ J       Date:  2010-09-11       Impact factor: 2.993

Review 2.  Impact of aldosterone antagonists on the substrate for atrial fibrillation: aldosterone promotes oxidative stress and atrial structural/electrical remodeling.

Authors:  Fadia Mayyas; Karem H Alzoubi; David R Van Wagoner
Journal:  Int J Cardiol       Date:  2013-08-15       Impact factor: 4.164

Review 3.  Atrial fibrillation: basic mechanisms, remodeling and triggers.

Authors:  Akiko Shiroshita-Takeshita; Bianca J J M Brundel; Stanley Nattel
Journal:  J Interv Card Electrophysiol       Date:  2005-09       Impact factor: 1.900

Review 4.  [New antiarrhythmic drugs for therapy of atrial fibrillation: II. Non-ion channel blockers].

Authors:  M Hammwöhner; A D'Alessandro; D Dobrev; P Kirchhof; A Goette
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2006-06

Review 5.  Antioxidant therapies for the management of atrial fibrillation.

Authors:  Tong Liu; Panagiotis Korantzopoulos; Guangping Li
Journal:  Cardiovasc Diagn Ther       Date:  2012-12

Review 6.  Lipid metabolites and their differential pro-arrhythmic profiles: of importance in the development of a new anti-arrhythmic pharmacology.

Authors:  Yangzhen Shao; Bjorn Redfors; David Benoist; Sigfus Gizurarson; Elmir Omerovic
Journal:  Mol Cell Biochem       Date:  2014-04-27       Impact factor: 3.396

Review 7.  Angiotensin II and angiotensin 1-7: which is their role in atrial fibrillation?

Authors:  Annamaria Mascolo; Konrad Urbanek; Antonella De Angelis; Maurizio Sessa; Cristina Scavone; Liberato Berrino; Giuseppe Massimo Claudio Rosano; Annalisa Capuano; Francesco Rossi
Journal:  Heart Fail Rev       Date:  2020-03       Impact factor: 4.214

8.  Post-operative atrial fibrillation is influenced by beta-blocker therapy but not by pre-operative atrial cellular electrophysiology.

Authors:  Antony J Workman; Davide Pau; Calum J Redpath; Gillian E Marshall; Julie A Russell; Kathleen A Kane; John Norrie; Andrew C Rankin
Journal:  J Cardiovasc Electrophysiol       Date:  2006-11

Review 9.  The renin-angiotensin-aldosterone system (RAAS) and cardiac arrhythmias.

Authors:  Shahriar Iravanian; Samuel C Dudley
Journal:  Heart Rhythm       Date:  2008-03-04       Impact factor: 6.343

10.  Rationale for and design of the CREATIVE-AF trial: randomized, double-blind, placebo-controlled, crossover study of the effect of irbesartan on oxidative stress and adhesion molecules in patients with persistent atrial fibrillation.

Authors:  Andreas Goette; Alessandra D'Alessandro; Alicja Bukowska; Siegfried Kropf; Christian Mewis; Christoph Stellbrink; Jürgen Tebbenjohanns; Christian Weiss; Uwe Lendeckel
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.